Conversely, bortezomib monotherapy has had poor outcomes in patients with metastatic breast cancer, whereas a study reported 11 months of progression-free survival without adverse events in patients with metastatic triple-negative breast cancer with TP53 mutations (73, 74). The gene discussed is TP53; the disease is triple-negative breast carcinoma.